<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575156</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/54</org_study_id>
    <nct_id>NCT03575156</nct_id>
  </id_info>
  <brief_title>Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis</brief_title>
  <acronym>MICROLUPS</acronym>
  <official_title>Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims at defining the role of circulating microparticles in the physiopathology of
      two rare auto-immune diseases: systemic lupus erythematosus (SLE) and systemic scleroderma
      (SSc). Microparticles might have an prognostic and diagnostic interest as well as potential
      for the discovery of new therapeutic strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) and systemic scleroderma (SSc) are two rare and
      potentially life-threatening auto-immune systemic diseases. There is an urgent need to
      describe prognostic factors and to discover new therapeutic pathways. Microparticles (MPs)
      are small extracellular vesicles formed from activated cells including endothelial cells and
      platelets. Preliminary data from our lab indicate that these MPs might play a key role in SLE
      and SSc physiopathology. In fact, MPs from patients with SLE aggregates with T regulator
      lymphocytes (LTregs) and decrease their activity, thereby promoting auto-immunity. Some works
      also indicate that MPs might cargo DNA to the immune system, also promoting auto-immunity.
      The investigators hypothesized that MPs levels might be a prognostic factor in SLE and SSc
      and that studying the molecular mechanisms involved could provide new therapeutic targets.

      Our study will recruit 100 patients with SLE or SSc followed in Bordeaux University Hospital.
      Among classical disease activity information, blood and urine samples will be collected at
      each visit to study circulating microparticles. Fundamental research will be realized on
      patients' sample to study molecular mechanisms involved.

      Clinical and biological disease activity, treatment and outcomes will be studied in
      correlation with MPs to describe their potential prognostic role. Patients will be followed
      at regular intervals as their usual follow-up would request. No extra visit will be needed
      and blood samples will be drawn at the same times as those drawn for clinical purposes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quantitative levels of circulating MPs between baseline and 12 months in the blood and urine samples of SLE and SSc patients</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity scores for SLE patients</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
    <description>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity scores for SSc patients</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
    <description>Rodnan score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of P-selectin levels (soluble and on platelets) in the blood and urine samples of SLE and SSc patients</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of FAS-ligand levels in the blood and urine samples of SLE and SSc</measure>
    <time_frame>At baseline (Day 0) and 12 months from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Systemic Scleroderma</condition>
  <arm_group>
    <arm_group_label>Systemic lupus erythematosus (SLE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>systemic scleroderma (SSc)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation</description>
    <arm_group_label>Systemic lupus erythematosus (SLE)</arm_group_label>
    <arm_group_label>systemic scleroderma (SSc)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>urine sample</intervention_name>
    <description>6 ml</description>
    <arm_group_label>Systemic lupus erythematosus (SLE)</arm_group_label>
    <arm_group_label>systemic scleroderma (SSc)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of systemic lupus erythematosus or systemic sclerosis;

          -  age â‰¥ 18 years;

          -  being affiliated to health insurance, willing to participate and to sign informed
             consent.

        Exclusion Criteria:

          -  pregnant or breastfeeding women;

          -  patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty
             by a judicial or administrative decision, minors, persons of legal age who are the
             object of a legal protection measure or unable to express their consent)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe RICHEZ, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU - Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe RICHEZ, Prof</last_name>
    <phone>(0)5 56 79 55 56</phone>
    <phone_ext>+33</phone_ext>
    <email>christophe.richez@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas BARNETCHE, PhD</last_name>
    <phone>(0)5.57.82.04.93</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.barnetche@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de rhumatologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe RICHEZ, Prof</last_name>
      <phone>(0)5.56.79.55.56</phone>
      <phone_ext>+33</phone_ext>
      <email>christophe.richez@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas BARNETCHE, PhD</last_name>
      <phone>(0)5.57.82.04.93</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.barnetche@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe RICHEZ, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Elise TRUCHETET, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel COUZI, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien SENESCHAL, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre DUFFAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Systemic Scleroderma</keyword>
  <keyword>autoimmunity</keyword>
  <keyword>microparticles</keyword>
  <keyword>platelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

